Harbour Investments
PRVB

Harbour Investments’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Harbour Investments’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,260
Closed -$34K – 3917
2021
Q3 		$34K Buy
5,260
+5,000
+1,923% +$32.1K ﹤0.01% 1998
2021
Q2 		$2K Hold
260
– – ﹤0.01% 3462
2021
Q1 		$3K Buy
+260
New +$3.66K ﹤0.01% 3155

Other funds holding PRVB

Sessa Capital
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Harbour Investments's PRVB Position: Q4 2021 in Review

Harbour Investments sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2021, closing a stake of 5,260 shares — an estimated $34K sold.

Harbour Investments first reported a position in PRVB in Q1 2021 and held it in 3 quarters. The position peaked at $34K in Q3 2021. 112 funds tracked by Wall St. Rank hold PRVB as of Q4 2021.

  • Harbour Investments reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 5,260 Provention Bio, Inc. Common Stock shares in Q4 2021, an estimated $34K.
  • Harbour Investments first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's Provention Bio, Inc. Common Stock position peaked at $34K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.